1. Home
  2. Labeler Index
  3. Golden State Medical Supply, Inc.
  4. 51407-680
  5. Product Images: Rizatriptan Benzoate

Product Images Rizatriptan Benzoate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Rizatriptan Benzoate NDC 51407-680 by Golden State Medical Supply, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

51407-679-03CB (PL).jpg - 51407 679 03CB (PL)

51407-679-03CB (PL).jpg - 51407 679 03CB (PL)

51407-680-03CB (PL).jpg - 51407 680 03CB (PL)

51407-680-03CB (PL).jpg - 51407 680 03CB (PL)

Not available.*

Figure 1: Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4†† - rizatriptan fig1

Figure 1: Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4†† - rizatriptan fig1

Figure 2: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in P - rizatriptan fig2

Figure 2: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in P - rizatriptan fig2

Figure 2 provides an estimated probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other medication for migraines over a 24-hour period following the initial dose of study treatment. This data was obtained from pooled Studies 1, 2, 3, and 4. The Kaplan-Meier plot shows the percentage of patients who took the second dose at different time points post-dose. Patients who did not use additional treatments were censored at 24 hours. The plot includes patients who had a headache response at 2 hours and those who did not respond to the initial dose. Remedication within 2 hours post-dose was not allowed.*

Figure 3: Estimated Probability of Achieving an Initial Headache Response with Rizatriptan Benzoate Orally Disintegrating Tablets by 2 Hours in Pooled Studies 5 and 6‡ - rizatriptan fig3

Figure 3: Estimated Probability of Achieving an Initial Headache Response with Rizatriptan Benzoate Orally Disintegrating Tablets by 2 Hours in Pooled Studies 5 and 6‡ - rizatriptan fig3

Figure 4: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Orally Disintegrating Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of - rizatriptan fig4

Figure 4: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Orally Disintegrating Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of - rizatriptan fig4

Figure 5: Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7 - rizatriptan fig5

Figure 5: Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7 - rizatriptan fig5

This is a figure titled "Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7". It shows the percentage of patients reporting no headache pain after taking Rizatriptan Benzoate 0D Tablets compared to a placebo. The graph displays percentages from 0% to 100%, with time intervals marked on the x-axis.*

Chemical Structure - rizatriptan str

Chemical Structure - rizatriptan str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.